Taisuke Tsuji
32 Papers
59 Citations
Taisuke Tsuji is an academic researcher. The author has contributed to research in topics: Medicine & Lung cancer. The author has an hindex of 8, co-authored 25 publications.
Chat about Author
Papers
Pleuroparenchymal fibroelastosis from a consecutive database: a rare disease entity?
Takeshi Nakatani,Toru Arai,Masanori Kitaichi,Masanori Akira,Kazunobu Tachibana,Chikatoshi Sugimoto,Aya Hirooka,Taisuke Tsuji,Shojiro Minomo,Seiji Hayashi,Yoshikazu Inoue +10 more
TL;DR: Idiopathic pleuroparenchymal fibroelastosis is an acceptable entity among IIPs and not as rare as previously reported, and hypothesized that PPFE was not a rare disease entity.
74
Dose escalation study of carboplatin–pemetrexed followed by maintenance pemetrexed for elderly patients with advanced nonsquamous nonsmall-cell lung cancer
Akihiro Tamiya,Motohiro Tamiya,Takayuki Shiroyama,M. Kanazu,A. Hirooka,Taisuke Tsuji,Naoko Morishita,Kazuhiro Asami,Hiroyuki Suzuki,Norio Okamoto,Kyoichi Okishio,Tomoya Kawaguchi,Tomonori Hirashima,Shinji Atagi,Ichiro Kawase +14 more
TL;DR: This combination of carboplatin at an area under the concentration-time curve (AUC) of 5, and 500 mg/m(2) pemetrexed, was determined to be the recommended dose for elderly patients with advanced nonsquamous NSCLC.
25
Phase II trial of carboplatin, S-1, and gefitinib as first-line triplet chemotherapy for advanced non-small cell lung cancer patients with activating epidermal growth factor receptor mutations.
Akihiro Tamiya,Motohiro Tamiya,Takayuki Shiroyama,Nobuhiko Saijo,Takeshi Nakatani,Shojiro Minomo,Taisuke Tsuji,Naoko Takeuchi,Naoki Omachi,Kanako Kurata,Hidekazu Suzuki,Norio Okamoto,Kyoichi Okishio,Tomonori Hirashima,Shinji Atagi +14 more
TL;DR: Combination chemotherapy with carboplatin, S-1, and gefitinib is efficacious and well tolerated as a first-line treatment in advanced NSCLC patients with activating EGFR mutations.
17
Analysis of the impact of lung cancer treatment on nontuberculous mycobacterial lung diseases
Taisuke Tsuji,Kazunari Tsuyuguchi,Kazunobu Tachibana,Yohei Kimura,Takehiko Kobayashi,Shojiro Minomo,Shinji Atagi,Akihide Matsumura,Seiji Hayashi,Katsuhiro Suzuki +9 more
TL;DR: Whether NTM lung disease should be treated during anti-cancer chemotherapy has not been not clarified by this study, but it is thought that anti-NTM therapy should be introduced after consideration of the worsening of symptoms and radiological findings associated with N TM lung disease.
15
OA08.05 Efficacy and Cerebrospinal Fluid Concentration of Afatinib in NSCLC Patients with EGFR Mutation Developing Leptomeningeal Carcinomatosis
Akihiro Tamiya,Motohiro Tamiya,Takashi Nishihara,Takayuki Shiroyama,Keiko Nakao,Taisuke Tsuji,Naoko Takeuchi,Shun-ichi Isa,Naoki Omachi,Norio Okamoto,Hidekazu Suzuki,Ayano Iwazaki,Kimie Imai,Tomonori Hirashima,Shinji Atagi +14 more
9